Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.31 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.31 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL536714 | 0.83 | TDP1 (0.36) | ALDH1A1 | |
| SCHEMBL11300378 | 0.75 | — | — | |
| SCHEMBL8846758 | 0.75 | — | — | |
| SCHEMBL15947892 | 0.75 | — | — | |
| Glycidol SCHEMBL1005345 | 0.72 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL27310323 | 0.72 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL2300986 | 0.72 | — | — | |
| SCHEMBL9549622 | 0.72 | TDP1 (0.41) | — | |
| SCHEMBL11592133 | 0.72 | — | — | |
| SCHEMBL27982754 | 0.70 | ALDH1A1 (0.40) | ALDH1A1SLC1A3SLC1A2SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048284-A1 | THERAPEUTIC COMPOUNDS | MELTZER PETER C | 2009-02-19 | — | — | US | disclosed |
| US-7439264-B2 | Therapeutic compounds | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2008-10-21 | — | — | US | disclosed |
| EP-1478356-A4 | THERAPEUTIC COMPOUNDS | HARVARD COLLEGE (US) | 2005-03-16 | — | — | EP | disclosed |
| EP-1478356-A2 | THERAPEUTIC COMPOUNDS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2004-11-24 | — | — | EP | disclosed |
| US-20030232827-A1 | Therapeutic compounds | WILMINGTON TRUST (LONDON) LIMITED, AS SECURITY AGENT (GB) | 2003-12-18 | — | — | US | disclosed |
| WO-2003066004-A2 | THERAPEUTIC COMPOUNDS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2003-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232827-A1 | Therapeutic compounds | SLC10A1, SLC6A2, SLC47A1 | ALDH1A1 1419/4885SLC1A3 37/4885SLC1A2 16/4885 |
| US-20090048284-A1 | THERAPEUTIC COMPOUNDS | SLC10A1, SLC6A2, SLC47A1 | ALDH1A1 1419/4885SLC1A3 37/4885SLC1A2 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.